Global Innovative Platforms Inc.

Overview

• Delaware corporation developing non-invasive breath and air analysis for animal health and agriculture.
• Core focus: a breath-based diagnostic platform to detect disease and assess treatment effectiveness in animals, starting with heartworm in dogs.
• Primary products: VOCAM Plus (gas chromatograph with AI processing), FROG (breath/air sampling device with a collection wand), and a breath capture device for dogs.
• Ellvin is the software platform that processes breath data and displays results on a smart device.
• Commercial goal: a Heartworm Breath Test (HB Test) that uses breath prints to detect heartworm earlier than current blood-based tests and to monitor treatment response.

Technology and product suite

• VOCAM Plus: Gas chromatograph capable of reading parts per trillion for breath sample analysis.
• Breath capture device: Collects shallow breath from dogs and adapts to different muzzle sizes.
• FROG: Device for non-breath samples (feed, water, soil, air) with an integrated collection wand.
• Ellvin: Proprietary AI software (controlled by Defiant Technologies) that analyzes chromatograms and presents results.
• HB Test: A three-component system (Breath Collection Device, VOCAM Plus, Ellvin) intended to detect heartworm and monitor therapy.
• Development status: Algorithm work for the HB Test began in March 2025. Planned studies include blinded confirmation and verification/validation in 2026 prior to commercialization.
• Sample testing: Access to approximately 60 dogs for sample collection, including 23 heartworm-positive dogs used in development. Initial studies included eight dogs; later notes reference 35 samples and reported 100% accuracy in a research setting.

Intellectual property and licenses

• Licensor: Defiant Technologies Inc.
• License scope: Exclusive rights for animal use worldwide to manufacture, use, sell, and import Licensed Products subject to certain exceptions; Know-How license is non-exclusive.
• Licensed assets include patents and technology related to gas chromatography, chemical sensing, preconcentrators, and microfabricated components.
• License payments: $10,000 upfront, $50,000 in the first quarter after the effective date, then $50,000 per quarter until $250,000 total. The company has paid $150,000 to date ($142,400 in fiscal year 2025).
• Royalty: 3% of net sales of Licensed Products worldwide during the license term.
• The company depends on Defiant’s VOCAM Plus technology; disputes or loss of access could hinder development and commercialization.

Market, strategy, and operations

• Strategy: Prioritize commercialization of the HB Test as a combined system rather than selling components separately.
• Commercialization plan: Use a network of commercial laboratories in the U.S. and Canada to analyze collected breath samples; units may be placed at animal healthcare facilities and billed per use via Bluetooth or 5G connectivity.
• Target market: Heartworm testing in dogs, with a path to adoption driven by regulatory and clinical advantages compared with blood-based antigen tests.
• Platform capabilities: Non-invasive breath and air analysis with potential to expand to a multi-disease panel (up to nine diseases) from a single breath sample.
• Regulatory stance: The company states no pre-market approval is required for animal-use devices in the U.S.; FDA provides oversight. The company may pursue regulatory submissions for expanded indications.
• Business model: Emphasis on an end-to-end platform and sample analysis network.

Financial position and performance

• Revenue: $0 for the years ended September 30, 2024 and September 30, 2025. The company billed and collected $85,000 after September 30, 2025 through the filing date.
• Retained deficit: Approximately $1,250,000 as of September 30, 2025.
• Going concern: External auditors included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern given the lack of operating revenue and ongoing expenses.
• Cash and liquidity: The company has limited to no operating income and relies on external financing to continue operations.
• Financing plans: The company indicates potential future debt or equity financing, with possible dilution to existing shareholders.
• License obligations: Ongoing quarterly payments toward the upfront commitment and a 3% royalty on net sales; $150,000 of the $250,000 upfront commitment has been paid.

Corporate structure and people

• Legal form: Delaware corporation; not listed on a national exchange.
• Headquarters: 570 Lexington Green Ln, Sanford, FL 32751. Approximately 500 sq ft of space is provided in-kind by the President for a term through 2025.
• Employees: One full-time executive, Andrew Brown (sole director and CEO). The company relies on subcontractors and consultants for legal, product, and operational support.
• Board and advisors: Board of Advisors includes eight named individuals (including Dr. Lindsay Starkey, Rob Tavzel, Bruce L. Truman), with additional advisors expected to be added.
• Intellectual property ownership: The company relies on licensed IP from Defiant rather than owning patents directly.

Risks and disclosures

• Liquidity risk and going concern due to lack of revenue and reliance on external financing.
• Dependence on the Defiant Technologies license and VOCAM Plus technology.
• Penny-stock considerations and potential dilution from future financing.
• Internal control weaknesses: The company reports material weaknesses and significant deficiencies in financial reporting controls as of September 30, 2025.
• Cybersecurity: Current practices are informal; the company plans to adopt a formal cybersecurity framework and may engage external expertise.
• Market risk: Breath analysis for animal health is an emerging field with uncertainty about adoption, accuracy, and competitive position.
• Regulatory risk: Additional regulatory requirements could arise if the company expands indications or product scope.

Key numerical details

• Dogs available for testing: ~60; 23 heartworm-positive in development study.
• Full-time employees: 1 (CEO, Andrew Brown); other work outsourced to contractors.
• Revenue: $0 for fiscal years ended 9/30/2024 and 9/30/2025; $85,000 billed/collected after 9/30/2025.
• Retained deficit: ~ $1,250,000 as of 9/30/2025.
• License payments: $150,000 paid toward a $250,000 upfront commitment; 3% royalty on net sales.
• Office address: 570 Lexington Green Ln, Sanford, FL 32751 (approx. 500 sq ft provided at no charge through 2025).
• Market status: OTCQX-traded; identified as an emerging growth company with JOBS Act transition period election.